TeneoBio, Inc. is a biotechnology company that is developing a new class of biologics, Human Heavy Chain Antibodies (UniAbs®), as therapeutics against cancer, autoimmunity, and infectious diseases. TeneoBio has several products in pre-clinical development for the treatment of multiple myeloma, prostate cancer, immune disorders and AIDS.
TeneoBio’s antibody discovery engine is based on UniRat®, a proprietary heavy chain only, human immunoglobulin transgenic rat. We apply a novel sequence-based discovery approach using NGS, bioinformatics and high-throughput recombinant protein expression. This approach identifies a large set of diverse UniAb® leads with broad epitope coverage of target antigens.
The high affinity and robust function of UniAbs combine antibody specificity with excellent developability. The UniAbs’ fully human VH domains, UniDabs®, are versatile building blocks that can be linked to Fc’s or serum albumin for the development of novel therapeutics with multi-specificity, increased potency and extended half-life.
To enable the development of platforms for T cell redirection, TeneoBio has produced many high-affinity UniAbs® specific for human CD3 and various tumor antigens. Such bispecific therapeutic antibodies against multiple myeloma cells are currently in preclinical development. Blockade of immune checkpoints has been shown to direct T cells against tumors for therapeutic benefit. TeneoBio has produced several such high-affinity UniDab® blockers against various checkpoint inhibitors, laying the foundation for multi-specific anti-cancer therapeutics in the immune-oncology space.